The company will invest the amount on new technology and manufacturing equipment at its facility in Holdrege, Nebraska.

BD already produces around 2 billion insulin syringes per annum. It averagely produces about 250,000 syringes per hour.

BD diabetes care worldwide president Ken Miller said: “About 40 percent of people with diabetes who inject insulin use syringes as part of their diabetes management regimen.

"This investment will provide benefits to this diabetes population and underscores our commitment to supply high-quality, industry-leading insulin syringes to patients."

In 1966, the company started operations at the 12,000ft² facility in Holdrege. The facility, which was later expanded to 350,000ft² space, manufactures 20 different BD products.

Across Nebraska, BD employs around 2,500 associates in four manufacturing facilities in Holdrege, Broken Bow and two in Columbus.

In August, BD secured approval from the US Food and Drug Administration (FDA) for its new syringe for administration of Humulin R U-500 insulin to the patients.

Humulin R U-500 insulin is indicated for patients with diabetes requiring more than 200 units of insulin per day.

Image: BD to invest $100m in its insulin syringe facility in US. Photo: courtesy of antpkr /